Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UDCA in Chinese Pediatric COVID-19 Patients
ChiCTR2200067226Phase 4Recruiting
- Sponsor
- Xiamen Children's Hospital
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ursodeoxycholic acid in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Xiamen Children's Hospital. Primary endpoints: Proportion of participants with clinical improvement and Ct value of COVID-19 nucleic acid in throat swabs. Started Dec 2022; status: recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200067226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067226.